Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamma-Delta T Cell Therapy for Hematological Malignancies Post-Allo-HSCT
NCT04764513Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2021
- Primary completion
- Apr 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of gamma-delta T cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), lymphoma, sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
gamma-delta T cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on NCT04764513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764513.